vs
Side-by-side financial comparison of Ceribell, Inc. (CBLL) and DYNEX CAPITAL INC (DX). Click either name above to swap in a different company.
DYNEX CAPITAL INC is the larger business by last-quarter revenue ($43.5M vs $24.8M, roughly 1.8× Ceribell, Inc.).
Ceribell, Inc. develops and commercializes innovative portable neurodiagnostic medical devices, focused on rapid non-invasive electroencephalogram (EEG) solutions for seizure detection. Its core products serve hospital emergency departments, intensive care units, and long-term care facilities, with primary markets across North America and ongoing global expansion efforts.
Dynex Capital Inc. is a publicly traded real estate investment trust headquartered in the United States. It specializes in investing in and managing a diversified portfolio of mortgage-backed securities, residential and commercial mortgage loans, and other mortgage-related assets. It delivers consistent returns to shareholders via regular dividends and long-term capital growth.
CBLL vs DX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $24.8M | $43.5M |
| Net Profit | $-13.5M | — |
| Gross Margin | 87.3% | — |
| Operating Margin | -58.9% | — |
| Net Margin | -54.6% | — |
| Revenue YoY | — | 531.3% |
| Net Profit YoY | — | — |
| EPS (diluted) | $-0.35 | $1.59 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $24.8M | $43.5M | ||
| Q3 25 | $22.6M | $30.6M | ||
| Q2 25 | $21.2M | $23.1M | ||
| Q1 25 | $20.5M | $17.1M | ||
| Q3 24 | $17.2M | — | ||
| Q1 24 | — | $-3.2M | ||
| Q4 22 | — | $6.2M | ||
| Q3 22 | — | $7.1M |
| Q4 25 | $-13.5M | — | ||
| Q3 25 | $-13.5M | $150.4M | ||
| Q2 25 | $-13.6M | $-13.6M | ||
| Q1 25 | $-12.8M | $-3.1M | ||
| Q3 24 | $-10.4M | — | ||
| Q1 24 | — | $40.1M | ||
| Q4 22 | — | $43.3M | ||
| Q3 22 | — | $-46.7M |
| Q4 25 | 87.3% | — | ||
| Q3 25 | 88.3% | — | ||
| Q2 25 | 88.1% | — | ||
| Q1 25 | 87.9% | — | ||
| Q3 24 | 87.3% | — | ||
| Q1 24 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — |
| Q4 25 | -58.9% | — | ||
| Q3 25 | -64.8% | — | ||
| Q2 25 | -70.5% | — | ||
| Q1 25 | -69.3% | — | ||
| Q3 24 | -57.8% | — | ||
| Q1 24 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — |
| Q4 25 | -54.6% | — | ||
| Q3 25 | -59.6% | 491.3% | ||
| Q2 25 | -64.4% | -58.8% | ||
| Q1 25 | -62.4% | -18.0% | ||
| Q3 24 | -60.6% | — | ||
| Q1 24 | — | -1256.8% | ||
| Q4 22 | — | 697.2% | ||
| Q3 22 | — | -655.3% |
| Q4 25 | $-0.35 | $1.59 | ||
| Q3 25 | $-0.37 | $1.08 | ||
| Q2 25 | $-0.38 | $-0.14 | ||
| Q1 25 | $-0.36 | $-0.06 | ||
| Q3 24 | $-1.85 | — | ||
| Q1 24 | — | $0.64 | ||
| Q4 22 | — | $0.44 | ||
| Q3 22 | — | $-1.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $159.3M | $531.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $155.3M | $2.5B |
| Total Assets | $195.8M | $17.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $159.3M | $531.0M | ||
| Q3 25 | $168.5M | $491.0M | ||
| Q2 25 | $177.4M | $387.5M | ||
| Q1 25 | $182.7M | $327.4M | ||
| Q3 24 | $14.1M | — | ||
| Q1 24 | — | $295.7M | ||
| Q4 22 | — | $332.0M | ||
| Q3 22 | — | $260.4M |
| Q4 25 | $155.3M | $2.5B | ||
| Q3 25 | $164.1M | $2.0B | ||
| Q2 25 | $172.2M | $1.6B | ||
| Q1 25 | $180.9M | $1.4B | ||
| Q3 24 | $-136.0M | — | ||
| Q1 24 | — | $958.5M | ||
| Q4 22 | — | $901.3M | ||
| Q3 22 | — | $771.3M |
| Q4 25 | $195.8M | $17.3B | ||
| Q3 25 | $199.5M | $14.2B | ||
| Q2 25 | $207.7M | $11.3B | ||
| Q1 25 | $213.5M | $9.0B | ||
| Q3 24 | $47.1M | — | ||
| Q1 24 | — | $6.3B | ||
| Q4 22 | — | $3.6B | ||
| Q3 22 | — | $4.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-10.8M | $120.8M |
| Free Cash FlowOCF − Capex | $-11.0M | — |
| FCF MarginFCF / Revenue | -44.2% | — |
| Capex IntensityCapex / Revenue | 0.7% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-41.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-10.8M | $120.8M | ||
| Q3 25 | $-11.1M | $68.3M | ||
| Q2 25 | $-7.5M | $31.9M | ||
| Q1 25 | $-11.4M | $6.4M | ||
| Q3 24 | — | — | ||
| Q1 24 | — | $-17.1M | ||
| Q4 22 | — | $30.1M | ||
| Q3 22 | — | $25.5M |
| Q4 25 | $-11.0M | — | ||
| Q3 25 | $-11.5M | — | ||
| Q2 25 | $-7.6M | — | ||
| Q1 25 | $-11.6M | — | ||
| Q3 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — |
| Q4 25 | -44.2% | — | ||
| Q3 25 | -50.8% | — | ||
| Q2 25 | -35.9% | — | ||
| Q1 25 | -56.4% | — | ||
| Q3 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — |
| Q4 25 | 0.7% | — | ||
| Q3 25 | 1.6% | — | ||
| Q2 25 | 0.3% | — | ||
| Q1 25 | 0.7% | — | ||
| Q3 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.45× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q1 24 | — | -0.43× | ||
| Q4 22 | — | 0.69× | ||
| Q3 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CBLL
| Products | $18.8M | 76% |
| Subscription | $6.0M | 24% |
DX
Segment breakdown not available.
